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Summary
Background Diabetes has been deﬁ ned on the basis of diﬀ erent biomarkers, including fasting plasma glucose (FPG), 
2-h plasma glucose in an oral glucose tolerance test (2hOGTT), and HbA1c. We assessed the eﬀ ect of diﬀ erent 
diagnostic deﬁ nitions on both the population prevalence of diabetes and the classiﬁ cation of previously undiagnosed 
individuals as having diabetes versus not having diabetes in a pooled analysis of data from population-based health 
examination surveys in diﬀ erent regions.
Methods We used data from 96 population-based health examination surveys that had measured at least two of the 
biomarkers used for deﬁ ning diabetes. Diabetes was deﬁ ned using HbA1c (HbA1c ≥6·5% or history of diabetes 
diagnosis or using insulin or oral hypoglycaemic drugs) compared with either FPG only or FPG-or-2hOGTT 
deﬁ nitions (FPG ≥7·0 mmol/L or 2hOGTT ≥11·1 mmol/L or history of diabetes or using insulin or oral 
hypoglycaemic drugs). We calculated diabetes prevalence, taking into account complex survey design and survey 
sample weights. We compared the prevalences of diabetes using diﬀ erent deﬁ nitions graphically and by regression 
analyses. We calculated sensitivity and speciﬁ city of diabetes diagnosis based on HbA1c compared with diagnosis 
based on glucose among previously undiagnosed individuals (ie, excluding those with history of diabetes or using 
insulin or oral hypoglycaemic drugs). We calculated sensitivity and speciﬁ city in each survey, and then pooled 
results using a random-eﬀ ects model. We assessed the sources of heterogeneity of sensitivity by meta-regressions 
for study characteristics selected a priori.
Findings Population prevalence of diabetes based on FPG-or-2hOGTT was correlated with prevalence based on FPG 
alone (r=0·98), but was higher by 2–6 percentage points at diﬀ erent prevalence levels. Prevalence based on HbA1c was 
lower than prevalence based on FPG in 42·8% of age–sex–survey groups and higher in another 41·6%; in the other 
15·6%, the two deﬁ nitions provided similar prevalence estimates. The variation across studies in the relation between 
glucose-based and HbA1c-based prevalences was partly related to participants’ age, followed by natural logarithm of 
per person gross domestic product, the year of survey, mean BMI, and whether the survey population was national, 
subnational, or from speciﬁ c communities. Diabetes deﬁ ned as HbA1c 6·5% or more had a pooled sensitivity of 
52·8% (95% CI 51·3–54·3%) and a pooled speciﬁ city of 99·74% (99·71–99·78%) compared with FPG 7·0 mmol/L or 
more for diagnosing previously undiagnosed participants; sensitivity compared with diabetes deﬁ ned based on FPG-
or-2hOGTT was 30·5% (28·7–32·3%). None of the preselected study-level characteristics explained the heterogeneity 
in the sensitivity of HbA1c versus FPG.
Interpretation Diﬀ erent biomarkers and deﬁ nitions for diabetes can provide diﬀ erent estimates of population 
prevalence of diabetes, and diﬀ erentially identify people without previous diagnosis as having diabetes. Using an 
HbA1c-based deﬁ nition alone in health surveys will not identify a substantial proportion of previously undiagnosed 
people who would be considered as having diabetes using a glucose-based test.
Funding Wellcome Trust, US National Institutes of Health.
Copyright © NCD Risk Factor Collaboration. Open Access article distributed under the terms of CC BY.
Introduction
Diabetes prevalence and diabetes-related deaths are 
rising in most parts of the world, at least partly fuelled by 
the worldwide increase in excess weight and adiposity.1–5 
This trend has created concerns about the health and 
functional consequences for patients, and costs for 
health systems.6–8 Tracking the epidemic and the 
progress of programmes aimed at reducing diabetes and 
its complications requires consistent and comparable 
measurement of the prevalence of diabetes and the 
coverage of drug and lifestyle interventions that slow 
diabetes progression and decrease the risk of 
complications.
Diﬀ erent biomarkers have been used to deﬁ ne 
diabetes, including fasting plasma glucose (FPG), 2-h 
plasma glucose in an oral glucose tolerance test 
(2hOGTT), and, more recently, HbA1c.9–15 Population-
based health surveys in diﬀ erent countries and at 
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diﬀ erent times have also used diﬀ erent biomarkers for 
glycaemia and diabetes, and thus deﬁ ne diabetes 
diﬀ erently. The variety of biomarkers and deﬁ nitions 
creates a challenge in consistently analysing diabetes 
prevalence across countries and over time, and in 
measuring what proportion of people with diabetes are 
diagnosed and receive eﬀ ective treatments for diabetes 
and its complications.1,16,17 Therefore, there is a need to 
understand how the use of diﬀ erent biomarkers and 
deﬁ nitions aﬀ ects the identiﬁ cation of diabetes cases 
and the resulting estimates of population prevalence. 
This need is particularly pressing because two of the 
nine global targets for non-communicable diseases set 
after the 2011 United Nations high-level meeting on 
non-communicable diseases require estimates of 
diabetes prevalence: to halt the rise in the prevalence of 
diabetes, and to achieve a 50% coverage of drug 
treatment and counselling, including glycaemic control, 
to prevent coronary heart disease and stroke in people at 
high risk of cardiovascular disease.4,18 Diabetes is also 
one of the four main non-com municable diseases for 
which there is a global target of 25% reduction in 
premature mortality by 2025 compared with 2010.4,18
Some studies have analysed the classiﬁ cation of 
individuals as having diabetes or compared prevalence 
estimates based on diﬀ erent deﬁ nitions in speciﬁ c 
cohorts, especially for HbA1c compared with either FPG 
or 2hOGTT.19–61 Most of these analyses were based on a 
single cohort and very few covered diﬀ erent geographical 
regions. Two pooled analyses of Asian and European 
cohorts, and a study in the Paciﬁ c and Indian Ocean 
islands, assessed how the prevalence of diabetes and the 
classiﬁ cation of individuals as having diabetes versus 
not having diabetes changed depending on whether 
diabetes was deﬁ ned by FPG or 2hOGTT.62–66 There is no 
pooling study for HbA1c, which can be measured easily 
in population-based surveys without the need for 
overnight fasting and has been approved by the 
American Diabetes Association and WHO as a 
diagnostic test for diabetes.11,14 However, a review of data 
from six countries reported that the sensitivity of 
diabetes diagnosis based on HbA1c compared with FPG 
ranged from 17% to 78%,67 raising concerns about ethnic 
variation of HbA1c-based deﬁ nition.17
We assessed the eﬀ ect of diagnostic deﬁ nitions both on 
the identiﬁ cation of diabetes in previously undiagnosed 
individuals and on the population prevalence estimates 
for diabetes in a pooled analysis of data from population-
based health examination surveys in diﬀ erent world 
regions.
Research in context
Evidence before this study
We reviewed studies included in the NCD Risk Factor 
Collaboration databases for comparisons of various diabetes 
deﬁ nitions. We also searched PubMed with the term ((A1c[Title/
Abstract]) AND Sensitivity[Title/Abstract]) AND Speciﬁ city[Title/
Abstract]) on April 13, 2015. We also searched the references of 
recent reviews and guidelines. We found some studies on the 
classiﬁ cation of individuals as having diabetes or on comparison 
of prevalence estimates based on diﬀ erent deﬁ nitions in speciﬁ c 
cohorts, especially for HbA1c compared with either fasting plasma 
glucose (FPG) or 2-h oral glucose tolerance test (2hOGTT). Most 
of these analyses were based on a single cohort and very few 
covered diﬀ erent world regions. Two pooled analyses of Asian and 
European cohorts, and a study in the Paciﬁ c and Indian Ocean 
islands, assessed how the prevalence of diabetes and the 
classiﬁ cation of individuals as having diabetes versus not having 
diabetes changed depending whether diabetes was based on FPG 
or on 2hOGTT. There is no pooling study for HbA1c and we 
identiﬁ ed only one review of data from six countries. Other 
studies compared diﬀ erent diabetes deﬁ nitions among people 
with speciﬁ c pre-existing diseases—eg, heart disease and 
tuberculosis. We also found some prospective studies that 
assessed how HbA1c predicts future incidence of diabetes or 
cardiovascular diseases with mixed results.
Added value of this study
This study is the ﬁ rst pooling of a large number of 
population-based data from diﬀ erent world regions that 
addresses how diﬀ erent deﬁ nitions of diabetes aﬀ ect both the 
total prevalence, and the identiﬁ cation of previously 
undiagnosed individuals. By pooling a large number of data 
sources, the overall meta-analytical ﬁ nding overcomes 
between-study variation, which can be probed in meta-
regressions. Furthermore, by having a large number of 
studies, and age–sex groups within each study, we were able 
to develop regressions to convert across diﬀ erent diabetes 
deﬁ nitions, which is essential for enhancing comparability 
over time and across countries in surveillance.
Implications of all the available evidence
The use of HbA1c in surveillance requires further consideration 
in terms of how it predicts, and helps prevent, diabetes 
complications and sequelae. As such studies are done, and to 
maximise comparability of results across surveys, the best 
approach in population-based health surveys is to measure 
FPG and deﬁ ne diabetes as FPG 7·0 mmol/L or more or history 
of diagnosis with diabetes or using insulin or oral 
hypoglycaemic drugs, as used in the global monitoring 
framework for prevention and control of non-communicable 
diseases. When HbA1c is used, it would be valuable to also 
measure FPG in a subsample of participants to provide 
information about how the two tests relate. The conversion 
regressions developed here can be used to convert prevalence 
based on FPG to that based on FPG-or-2hOGTT. 
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Methods
Study design
We aimed to answer two questions. First, how does the 
estimated prevalence of diabetes in a population change 
when the new deﬁ nition of diabetes based on HbA1c is 
used compared with earlier deﬁ nitions based on blood 
glucose? Second, how does the new deﬁ nition of diabetes 
based on HbA1c compare with earlier deﬁ nitions in 
identifying previously undiagnosed people with diabetes, 
as measured by the sensitivity and speciﬁ city of the new 
deﬁ nition with respect to the previous ones? We further 
assessed whether sensitivity varied by the characteristics 
of the study population, because this possible variation is 
a source of concern about the generalisability of HbA1c as 
a diagnostic and surveillance measure.17,67–70
For the HbA1c-based deﬁ nition of diabetes, we used 
HbA1c of 6·5% or more, or history of diagnosis with 
diabetes or using insulin or oral hypoglycaemic drugs.11 
For deﬁ nitions based on blood glucose, we used either 
the American Diabetes Association deﬁ nition of FPG of 
7·0 mmol/L or more, or history of diagnosis with 
diabetes or using insulin or oral hypoglycaemic drugs 
(which is also used in the global monitoring framework 
for prevention and control of non-communicable 
diseases),12,18 or the WHO deﬁ nition of FPG of 
7·0 mmol/L or more, or 2hOGTT of 11·1 mmol/L or 
more, or history of diabetes or using insulin or oral 
hypoglycaemic drugs.9,10
Data sources
We used population-based data collated by the NCD Risk 
Factor Collaboration (NCD-RisC), a worldwide network 
of health researchers and practitioners who, together 
with WHO, have collated a large database of population-
based health examination surveys and epidemiological 
studies of cardiometabolic risk factors. All data sources 
were checked by at least two independent reviewers as 
being representative of a national, subnational, or 
community population, and for study quality indicators 
such as fasting duration and the protocol for OGTT. We 
excluded surveys that had not used a standard glucose 
load for OGTT. Within each survey, we included 
participants aged 18 years and older who were not 
pregnant and had fasted at least for 6 h before 
measurement as a part of the survey instructions. We 
excluded HbA1c data from before the year 2000 to 
minimise the use of non-standard assays.71 We also 
excluded surveys that had measured a biomarker only 
among participants with a high value of another—eg, 
studies in which FPG was only measured in participants 
with HbA1c above a prespeciﬁ ed value, because the 
relation between the two measurements might be 
Figure 1: Study and data inclusion
FPG=fasting plasma glucose. 2hOGTT=2-h oral glucose tolerance test. *The meta-analyses used inverse of variance as survey weights; sensitivity or speciﬁ city of either 0% or 100% would make the 
corresponding variance zero, and therefore the inverse of variance inﬁ nite. 
68 surveys (200 983 participants) with individual-level 
 data for at least two glucose biomarkers
68 surveys (190 516 participants)
51 surveys (143 651 participants) included in
meta-analyses of diagnostic sensitivity and specificity
of glucose biomarkers
27 surveys (86 312 participants) with individual-level 
  data for HbA1c and FPG
 9 surveys (27 482 participants) with individual-level 
  data for HbA1c, FPG, and 2hOGTT
 33 surveys (84 821 participants) with individual-level 
  data for FPG and 2hOGTT
10 467 participants excluded
 8148 aged <18 years or were pregnant 
 2319 had not fasted or had unacceptable 
  fasting duration (<6 or >24 h)
Exclusions
 11 surveys (29 381 participants) were follow-ups 
  of other studies included in the analysis
13 863 participants had diagnosed diabetes or were 
  taking diabetes drugs
140 participants had data for only HbA1c and
2hOGTT, but not FPG
 6 surveys (3481 participants) with undefinable 
  sensitivity (no undiagnosed diabetics) or with 
  either sensitivity or specificity of 0% or 100%*
29 surveys (148 498 participants) with summarised 
 prevalence data for at least two diabetes definitions
68 surveys (184 345 participants) with individual-level data 
29 surveys (148 498 participants) with summarised 
 prevalence data
96 surveys (331 288 participants) with data for at least 
       two diabetes definitions included in analysis of 
       diabetes prevalence
Exclusions
1 survey (154 participants) plus an 
 additional 1401 participants were in 
 age–sex groups with sample size <25
6171 particpants excluded
 3532 participants did not have data for 
  least two diabetes definitions
 2639 participants had missing 
  primary sampling unit, strata or 
  sample weight where complex 
  sample design existed
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diﬀ erent in this prescreened group compared with the 
whole sample. The appendix shows details of individual 
surveys.
We restricted the analysis of sensitivity and speciﬁ city 
to people without a history of diabetes diagnosis, because 
previous diagnosis and the use of drug treatments 
probably aﬀ ect the concentrations of biomarkers used to 
diagnose diabetes. History of diabetes diagnosis was 
established with survey-speciﬁ c questions, such as “have 
you ever been told by a doctor or other health professional 
that you have diabetes?” or the combination of “do you 
now have, or have you ever had diabetes?” and “were you 
told by a doctor that you had diabetes?”. We also excluded 
follow-up surveys of closed cohorts from the analysis of 
sensitivity and speciﬁ city because active surveillance 
within a cohort shifts participants from undiagnosed to 
diagnosed status at each follow-up, thus aﬀ ecting the 
composition of undiagnosed cases.
Statistical analysis
We calculated diabetes prevalence by sex and age group, 
taking into account complex survey design and survey 
sample weights when relevant. We excluded age–sex 
groups with fewer than 25 participants when calculating 
prevalence because the sampling error of estimated 
prevalence can bias the associations between prevalences 
based on diﬀ erent deﬁ nitions. Some surveys had 
measured HbA1c or FPG in all participants, but had not 
measured 2hOGTT among people with diagnosed 
diabetes. These previously diagnosed participants were 
included in calculation of diabetes prevalence because 
their exclusion would underestimate diabetes prevalence. 
Furthermore, some surveys measured 2hOGTT in only a 
subset of people without history of diabetes diagnosis, 
generally for logistical or cost reasons. Simply combining 
these participants with previously diagnosed participants 
might overestimate diabetes prevalence based on 
2hOGTT. To account for these missing measurements, 
and to avoid overestimation of diabetes prevalence, we 
recalculated the survey sample weights for these 
participants as the original sample weights divided by 
weighted proportion of non-diabetic participants with 
data. This approach is similar to that used in the US 
National Health and Nutrition Examination Survey for 
their 2hOGTT sample weights.72 A similar approach was 
taken in a few surveys that had measured HbA1c in all 
participants, but had not measured FPG among people 
diagnosed with diabetes.
We compared graphically the prevalences of diabetes 
using diﬀ erent deﬁ nitions. We also did regression 
analyses of the relation between diabetes deﬁ ned (1) on 
the basis of FPG-or-2hOGTT versus on the basis of FPG 
only and (2) on the basis of HbA1c versus on the basis of 
FPG. We did not do a regression for diabetes prevalence 
based on HbA1c versus prevalence based on FPG-or-
2hOGTT because very few surveys had data for both 
2hOGTT and HbA1c, leading to unstable regression 
coeﬃ  cients. We probit-transformed diabetes prevalence 
because it provided better ﬁ t to the data and it avoids 
predicting prevalences that are less than 0 or greater 
Figure 2: Prevalence of diabetes deﬁ ned by FPG-or-2hOGTT versus by FPG only
FPG-or-2hOGTT deﬁ nition was FPG 7·0 mmol/L or more, or 2hOGTT 11·1 mmol/L or more, or history of diabetes or 
using insulin or oral hypoglycaemic drugs. FPG only deﬁ nition was FPG 7·0 mmol/L or more, or history of diabetes or 
using insulin or oral hypoglycaemic drugs. Each point shows one age–sex group in one survey. Table 1 shows the 
relation summarised as regression coeﬃ  cients. FPG=fasting plasma glucose. 2hOGTT=2-h oral glucose tolerance test.
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Coeﬃ  cient (95% CI) p value Univariate 
R2*
Semipartial 
R2†
Intercept 0·135 (–0·020 to 0·290) 0·0872 NA NA
Probit-transformed prevalence of 
diabetes based on FPG
0·903 (0·880 to 0·927) <0·0001 0·963 0·368
Mean age of age–sex group (per 
10 years older)
0·048 (0·039 to 0·056) <0·0001 0·444 0·008
Study midyear (per one more 
recent year since 1976)
–0·001 (–0·002 to 0·000) 0·1643 0·003 <0·001
Natural logarithm of per person 
gross domestic product
–0·033 (–0·046 to –0·019) <0·0001 0·004 0·001
Mean BMI 0·000 (–0·004 to 0·004) 0·9057 0·092 <0·001
Study representativeness ·· ·· 0·021 0·001
National Reference ·· ·· ··
Subnational –0·031 (–0·070 to 0·008) 0·1141 ·· ··
Community –0·070 (–0·101 to –0·039) <0·0001 ·· ··
FPG=fasting plasma glucose. 2hOGTT=2-h oral glucose tolerance test. *Calculated by regressing against each 
independent variable alone; equals the square of the correlation coeﬃ  cient. †Shows how much R2 decreases if that 
independent variable is removed from the full model; the overall R2 for the model was 0·973. 
Table 1: Regression coeﬃ  cients for the relation between probit-transformed prevalence of diabetes 
based on FPG-or-2hOGTT versus diabetes based on FPG only
See Online for appendix
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than 1. We considered regression models with alternative 
covariates and speciﬁ cations, and chose the best model 
using the Bayesian information criterion, which measures 
the relative goodness of ﬁ t of a model; it rewards how well 
the model ﬁ ts the data but discourages overﬁ tting.73 The 
regressions included age (mean age of each age–sex 
group); the years over which each survey collected data (as 
the midyear of the period of data collection; appendix); 
national income (natural logarithm of per person gross 
domestic product) in the survey country and year; whether 
the study was representative of a national, subnational, or 
community population; and mean BMI for each age–sex 
group. Sex was excluded from the regressions on the basis 
of the Bayesian information criterion. The regression of 
diabetes prevalence based on HbA1c against diabetes 
prevalence based on FPG, for which there were more data, 
also included terms for geographical region as random 
eﬀ ects on the basis of Bayesian information criterion; 
these random eﬀ ects account for diﬀ erences in the 
relationship by region. Two regions consisted of high-
income countries, as in previous global analyses5,74—high-
income Asia Paciﬁ c (consisting of Japan, Singapore, and 
Coeﬃ  cient (95% CI) p value* Univariate R²† Semipartial R²‡
Intercept –1·761 (–2·229 to –1·266) <0·0001 NA NA
Probit-transformed prevalence of diabetes based on FPG 0·799 (0·763 to 0·835) <0·0001 0·915 0·075
Mean age of age–sex group (per 10 years older) 0·052 (0·042 to 0·062) <0·0001 0·601 0·011
Study midyear (per one more recent year since 2000) 0·012 (0·009 to 0·015) <0·0001 0·014 0·006
Natural logarithm of per person gross domestic product 0·076 (0·035 to 0·114) 0·0001 0·052 0·003
Mean BMI 0·018 (0·010 to 0·027) <0·0001 0·022 0·002
Study representativeness ·· ·· 0·013 0·004
National Reference ·· ·· ··
Subnational –0·004 (–0·047 to 0·040) 0·8758 ·· ··
Community 0·090 (0·060 to 0·119) <0·0001 ·· ··
The appendix shows regional random eﬀ ects. FPG=fasting plasma glucose. *p values using likelihood ratio test, which compares the likelihood of the models with and 
without the variable of interest.78 †Calculated by regressing against each independent variable alone, without the regional random eﬀ ect; equals the square of the correlation 
coeﬃ  cient. ‡Is the decrease of R² if one of the independent variables is removed from the full model; however, traditional R² is not clearly deﬁ ned for mixed-eﬀ ect models, we 
have used the conditional R² that describes the proportion of variance explained by both ﬁ xed and random factors.79 The overall conditional R² for the model was 0·949. 
Table 2: Regression coeﬃ  cients for the association between probit-transformed prevalence of diabetes based on HbA1c and probit-transformed 
prevalence based on FPG
Figure 3: Prevalence of diabetes deﬁ ned by HbA1c only versus prevalence deﬁ ned by (A) FPG only, and (B) FPG-or-2hOGTT
HbA1c deﬁ nition was HbA1c 6·5% or more, or history of diabetes, or using insulin or oral hypoglycaemic drugs. FPG only deﬁ nition was FPG 7·0 mmol/L or more, or 
history of diabetes or using insulin or oral hypoglycaemic drugs. FPG-or-2hOGTT deﬁ nition was FPG 7·0 mmol/L or more, or 2hOGTT 11·1 mmol/L or more, or history 
of diabetes or using insulin or oral hypoglycaemic drugs. Each point shows one age–sex group in one survey. Table 2 shows the relations summarised as regression 
coeﬃ  cients. FPG=fasting plasma glucose. 2hOGTT=2-h oral glucose tolerance test.
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South Korea) and high-income western countries 
(consisting of countries in Australasia, North America, 
and western Europe). The other countries were divided 
based on their geography into central and eastern Europe; 
central Asia, Middle East and north Africa; east and 
southeast Asia; south Asia; Latin America and the 
Caribbean; and sub-Saharan Africa.
We plotted the residuals of the regression models against 
the main independent variable (probit-transformed FPG-
based prevalence), and found no evidence of hetero-
scedasticity in the residuals. We also report the univariate 
and semipartial R² for each of the variables in the 
regression model. Univariate R² measures how much of 
the variance is explained by each independent variable. 
Semipartial R² measures the contribution of each variable 
to the total explained variance, conditional on the presence 
of the other model variables.75
We calculated sensitivity and speciﬁ city of diagnosis 
separately in each survey, and then pooled the sensitivities 
and speciﬁ cities across surveys with a random-eﬀ ects 
model.76 We examined the sources of heterogeneity in 
sensitivity and speciﬁ city with metaregressions and 
a-priori selected study characteristics: mean age, 
proportion of male participants, midyear of study data 
collection period; sample size; prevalence of undiagnosed 
diabetes in the survey; whether the survey was 
representative of a national, subnational, or community 
population; geographical region; national income in the 
survey country and year; and mean haemoglobin 
concentration in the survey country and year. We did the 
analyses with Stata (version 12.2) and R (version 3.0.3).
Role of the funding source
The funders had no role in study design, data collection, 
analysis, or interpretation, or writing of the report. SF, 
YL, and BZ had full access to all the data. ME was 
responsible for submitting the Article for publication.
Results
After exclusions, we included 96 population-based health 
examination surveys of 331 288 participants (ﬁ gure 1). 
46 surveys were from Australia, USA, and western Europe; 
18 from east and southeast Asia; ten from Latin America 
and the Caribbean; seven from Oceania; six from sub-
Saharan Africa; ﬁ ve from south Asia; three from the 
Middle East and north Africa; and one from central and 
eastern Europe. All 96 studies measured FPG; 47 also 
measured 2hOGTT and 63 measured HbA1c (appendix). 
14 of these studies measured all three biomarkers. All but 
three studies of the 47 studies used for comparing 
prevalence based on FPG alone versus based on FPG-or-
2hOGTT measured FPG in a laboratory; two of the 
remaining studies used a portable unit, and we did not 
have information for the remaining study. All studies 
measured 2hOGTT in a laboratory. All but one of the 
63 studies used for comparing glucose-based and 
HbA1c-based prevalences measured glucose in a laboratory; 
the remaining study measured FPG with a portable unit. 
An enzymatic method was used to measure FPG in 65 of 
the 92 studies that had measured FPG in a laboratory, but 
we had no information for the remaining 27 studies. In all 
63 studies, HbA1c was measured in a laboratory; in 40 of 
these studies, the measurements were done by 
chromatography or immunoassay. No information was 
available for the remaining 23. Such a dominance of 
laboratory-based measurements prevented us from 
assessing the role of measurement method as a source of 
variation because laboratory-based methods are equally 
acceptable, especially for glucose.77
Diabetes prevalence ranged from 0% in people younger 
than 40 years of age in some surveys to about 70% in 
Number 
of 
surveys
Sensitivity Speciﬁ city
(%; 95% CI) I² (%; 95% CI) I2
HbA1c vs FPG 27 52·82 (51·33–54·30) 97·6% 99·74 (99·71–99·78) 98·2%
HbA1c vs 2hOGTT 9 37·16 (35·05–39·28) 97·6% 99·84 (99·79–99·89) 97·3%
HbA1c vs FPG-or-2hOGTT 9 30·46 (28·66–32·25) 97·9% 99·69 (99·63–99·76) 98·0%
FPG vs 2hOGTT 33 54·42 (53·26–55·57) 96·9% 98·90 (98·83–98·97) 94·4%
The appendix shows detailed results of these meta-analyses. Diabetes was deﬁ ned as HbA1c ≥6·5%, FPG ≥7·0 mmol/L, 
and 2hOGTT ≥11·1 mmol/L. FPG=fasting plasma glucose. 2hOGTT=2-h oral glucose tolerance test. 
Table 3: Pooled sensitivity and speciﬁ city of diabetes diagnosis using diﬀ erent deﬁ nitions among 
participants without diagnosed diabetes
Mean diﬀ erence in 
sensitivity 
(percentage points; 
95% CI)
p value
Mean age (per 10 years older)  –4·1 (–12·7 to 4·5) 0·3361
Percent male participants (per 10% more male)  4·6 (–9·0 to 18·2) 0·4901
Study midyear (per one more recent year) 1·2 (–0·9 to 3·2) 0·2566
Region ·· 0·2097
High-income western countries Reference group ··
East, south, and southeast Asia 21·0 (–0·3 to 42·2) ··
Latin America and the Caribbean 8·5 (–17·9 to 34·9) ··
Sub-Saharan Africa  17·6 (–14·1 to 49·2) ··
Study representativeness ·· 0·0915
National Reference group ··
Subnational 1·7 (–28·6 to 31·9) ··
Community 21·4 (2·1 to 40·8) ··
Prevalence of undiagnosed diabetes (percentage point higher 
undiagnosed diabetes)
–0·7 (–4·0 to 2·6) 0·6780
Sample size (per 1000 participants without diagnosed diabetes) –1·6 (–4·6 to 1·4) 0·2730
Natural logarithm of per person gross domestic product –6·5 (–17·6 to 4·6) 0·2410
Mean haemoglobin (per g/L)* –2·0 (–4·1 to 0·2) 0·0677
We used a HbA1c deﬁ nition of 6·5% or more and a FPG deﬁ nition of 7·0 mmol/L or more. FPG=fasting plasma glucose. 
*Reliable mean haemoglobin data were available only for women of child-bearing age.82 The national mean for each 
country-year was used for both men and women; restricting the analysis to women led to similar results, with a mean 
diﬀ erence of –2·1 (–4·5 to 0·3, p=0·0929).
Table 4: Univariate metaregression coeﬃ  cients for sensitivity of HbA1c versus FPG in participants 
without diagnosed diabetes
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middle-aged and older adults in Nauru (ﬁ gure 2). 
Prevalence of diabetes based on FPG alone was lower 
than that based on FPG-or-2hOGTT, by 2–6 percentage 
points at diﬀ erent prevalence levels, although prevalences 
estimated using these two glucose-based measures were 
highly correlated (r=0·98; ﬁ gure 2). Tables 1 and 2 show 
results of the regression analyses. After accounting for 
prevalence based on FPG, prevalence based on FPG-or-
2hOGTT increased with age—ie, prevalence based on 
FPG-or-2hOGTT rose more sharply with age than did 
prevalence based on FPG only.65,80,81
HbA1c-based prevalences were lower than those based 
on FPG for 42·8% of age–sex–survey groups and higher 
in another 41·6%; in the other 15·6%, the two deﬁ nitions 
gave similar prevalences (ﬁ gure 3). In the regression 
analysis, prevalence based on HbA1c was on average 
slightly lower than prevalence based on FPG (table 2). The 
most important determinant of variation between these 
two prevalences was age, with some eﬀ ect from national 
income, mean BMI, year of survey, and whether the 
survey was representative of a national, subnational, or 
community population. After accounting for prevalence 
based on FPG, prevalence based on HbA1c increased with 
age, national income, mean BMI, and the year of survey. 
After accounting for prevalence based on FPG, HbA1c-
based prevalence was higher in south Asia than in other 
regions, and was lower in high-income regions than in 
other regions (appendix).
Diabetes deﬁ ned as HbA1c of 6·5% or more had a 
pooled sensitivity of 52·8% (95% CI 51·3–54·3) compared 
with a deﬁ nition of FPG of 7·0 mmol/L or more for 
diagnosing participants without a previous diagnosis of 
diabetes. This ﬁ nding suggests that 47·2% of participants 
without a previous diagnosis of diabetes who would be 
considered to have diabetes based on their FPG 
concentration would not be considered to have diabetes 
with an HbA1c test (table 3). The sensitivity of HbA1c varied 
substantially across studies (I² of 97·6%), ranging from 
13·0% to 93·2% (appendix pp 11–12). HbA1c had even 
lower sensitivity when compared with deﬁ ning diabetes 
based on FPG-or-2hOGTT (30·5%, 95% CI 28·7–32·3). 
None of the preselected study-level characteristics 
explained the heterogeneity in the sensitivity of HbA1c 
versus FPG (all p values >0·06; table 4). Pooled speciﬁ city 
of HbA1c was 99·74% (95% CI 99·71–99·78) relative to 
FPG and 99·69% (99·63–99·76) relative to FPG-or-
2hOGTT, suggesting few false positives compared with 
glucose-based deﬁ nitions.
Lowering the threshold for diabetes by HbA1c from 6·5% 
to 6·3% (a cutoﬀ  suggested by some studies49,50) increased 
sensitivity compared with the FPG-based deﬁ nition from 
52·8% to 64·3% while maintaining a high speciﬁ city at 
99·53%. Lowering it further to 6·1% increased sensitivity 
to 72·8% but the speciﬁ city would drop to 99·08%, 
resulting in more false positives. Follow-up studies are 
needed to establish how these cutoﬀ s predict complications 
and sequelae in newly diagnosed patients.83,84
Discussion
In this large international pooled analysis of population-
based health examination surveys, we found that the use of 
diﬀ erent biomarkers and deﬁ nitions for diabetes can lead 
to diﬀ erent estimates of population prevalence of diabetes, 
with the highest prevalence when diabetes is deﬁ ned on 
the basis of FPG-or-2hOGTT and the lowest when based 
on HbA1c alone. For example, at an FPG-based prevalence 
of 10%, similar to the age-standardised global prevalence 
of diabetes in adults aged 25 years and older in 2008,1 
prevalence based on FPG-or-2hOGTT would be about 13% 
according to the relation in ﬁ gure 2. The variation across 
studies in the relation between glucose-based and 
HbA1c-based prevalences was partly related to age, followed 
by national income, mean BMI, the year of survey, and 
whether the survey population was national, subnational, 
or from speciﬁ c communities. The reasons for additional 
regional eﬀ ects—higher HbA1c-based prevalence in south 
Asia and lower prevalence in high-income regions than in 
other regions after accounting for prevalence based on 
FPG—are unknown, but they might be a result of true 
physiological diﬀ erences; for example, related to red blood 
cell turnover (itself related to anaemia and iron status), 
which aﬀ ects HbA1c, or related to glucose dysregulation 
during fasting and non-fasting which are captured by 
HbA1c.85 Establishing these reasons requires multicentre 
studies with consistent methods and protocols and data for 
phenotypical factors that might aﬀ ect the relation between 
glucose and HbA1c. For now, they are unexplained 
empirical results that should be taken into account when 
using surveys from diﬀ erent regions.
Similarly, diﬀ erent deﬁ nitions identiﬁ ed diﬀ erent 
people without a previous diagnosis as having diabetes. 
Speciﬁ cally, use of an HbA1c-based deﬁ nition would not 
identify almost half of the undiagnosed cases that could 
be detected with a FPG test, and more than three-quarters 
of undiagnosed cases that would be detected by FPG and 
2hOGTT combined, but it would lead to few false 
positives compared with glucose-based deﬁ nitions. 
Inversely, using a glucose-based test alone would not 
identify some people who would be considered as having 
diabetes with HbA1c.
Our results, based on a large number of surveys from 
diﬀ erent regions, are consistent with previous smaller 
studies that compared diﬀ erent diabetes deﬁ nitions. 
Diabetes prevalence based on FPG-or-2hOGTT was 
higher than prevalence based on FPG alone by 18% in an 
analysis of 13 European cohorts and by 6% in an analysis 
of 11 Asian cohorts.63,64 A previous comparison of diabetes 
prevalence across six studies, including two analysed 
here, reported that diagnostic sensitivity for HbA1c 
compared with 2hOGTT ranged from 17% to 78%,67 
which is consistent with the results of our analysis. 
However, this study also found surprisingly low 
speciﬁ cities for HbA1c compared with ours.67 Other 
single-cohort studies also generally reported low but 
variable sensitivities and high speciﬁ cities for HbA1c 
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relative to blood glucose. Several studies86–89 assessed the 
optimal cutoﬀ  for HbA1c in diﬀ erent populations and all 
reported values lower than 6·5%, which is consistent 
with our ﬁ nding that lowering the threshold would 
increase sensitivity while preserving high speciﬁ city. One 
small study90 examined the eﬀ ect of anaemia on 
diagnostic accuracy of HbA1c and reported higher 
sensitivity (than with FPG) in patients with anaemia, 
which is consistent with our results.
Our analysis, which focused on questions that are 
relevant for population-based surveillance of diabetes and 
monitoring treatment coverage, has several strengths. We 
pooled data from a large number of population-based 
surveys from diﬀ erent world regions, thereby increasing 
both the precision of our estimates and their 
generalisability compared with analyses of one or a small 
number of cohorts. We used consistent eligibility and 
inclusion criteria, and assessed whether the surveys met 
these criteria. In particular, we only used surveys that had 
rigorous protocols for fasting duration and for OGTT. 
Furthermore, most surveys measured glucose and HbA1c 
in a laboratory. We also assessed the sources of 
heterogeneity in how diagnostic criteria compare across 
surveys, which could not be done in previous analyses 
because they included few surveys.
Our results should be interpreted with some limitations 
in mind. We had few studies from some regions 
including sub-Saharan Africa, south Asia, the Middle 
East and north Africa, and central and eastern Europe. 
 We analysed the surveys with consistent methods but 
surveys might have diﬀ ered in details such as the exact 
limit for fasting duration beyond the 6-h limit imposed 
by us. Because HbA1c measurement has changed over 
time,91–99 and to minimise the use of non-standard assays, 
we did not include any HbA1c data from before the year 
2000.71 Despite this exclusion, and the fact that all of our 
surveys had measured HbA1c in a laboratory, HbA1c 
measurements can vary between laboratories and 
instruments,100 about which we did not have complete 
data. For the same reason, we could not standardise the 
HbA1c data to account for diﬀ erent assays and instruments 
used in measurement. Nutritional status—especially 
iron deﬁ ciency—anaemia, malaria and other parasitic 
diseases, living at high altitudes, and high prevalence of 
haemoglobinopathies can aﬀ ect HbA1c,101 but could not be 
assessed as a source of heterogeneity beyond their eﬀ ects 
through mean haemoglobin concentration. Similarly, 
data for glucose can be aﬀ ected by unrecorded factors 
such as inaccurate information about fasting, ﬂ uctuations 
in diet and physical activity in days before measurement, 
and how samples were handled, including time between 
drawing blood and laboratory analysis and the type of 
tube used for collecting and storing blood. 
Although we assessed the role of geographical region, 
we did not have data for the ethnic composition of 
participants in each survey. By their nature, health 
examination surveys used for population-based 
surveillance use a single measurement for each 
participant, whereas diagnosis in a clinical setting might 
repeat the measurements based on the ﬁ rst test. The use 
of a single test is aﬀ ected by within-individual and even 
within-laboratory variation, and could lead to 
misclassiﬁ cation of some individuals.99 Finally, we did 
not have longitudinal follow-up data to assess sensitivity 
and speciﬁ city for diagnosis using one deﬁ nition (or one 
cutoﬀ  value of HbA1c) compared to another or for 
development of diabetes complications and sequelae that 
contribute the bulk of the public health burden of 
diabetes. Such data are not available in population-based 
surveys because surveys are typically cross-sectional.
There is no gold standard deﬁ nition that captures the 
phenotypic complexity of diabetes and the risk of its 
microvascular and macrovascular complications, 
although 2hOGTT is often treated as the most reliable 
test.15,102,103 In clinical practice, physicians follow an 
analytical process to diagnose diabetes, in which diﬀ erent 
sequences of glucose biomarkers are used depending on 
factors such as a patient’s age and symptoms; those with 
high levels of one biomarker (eg, HbA1c) might be asked 
to have additional measurements of the same or a 
diﬀ erent biomarker, and be monitored over time to 
decide on the best course of treatment. The process 
might vary from patient to patient to account for their 
unique characteristics, and might further vary from 
physician to physician based on available infrastructure 
and medical resources. In surveillance using population-
based surveys, which provides evidence for policies and 
programmes related to whole populations, repeated 
measurements are virtually impossible. Therefore, 
considerations about diabetes deﬁ nition and diagnosis 
are diﬀ erent from those of clinical practice, and the 
emphasis is on comparability of deﬁ nitions over time 
and across populations. Our results provide much 
needed empirical evidence for planning global 
surveillance of diabetes and coverage of its interventions. 
Speciﬁ cally, despite its relative ease of use, using HbA1c 
alone in health surveys might miss some previously 
undiagnosed people who would be considered as having 
diabetes using a glucose-based test, and thus could 
beneﬁ t from lifestyle and treatment interventions. Even 
so, 2hOGTT is diﬃ  cult to measure even in a clinical 
setting, let alone in population-based surveys. Of 493 
worldwide population-based diabetes data sources 
between 1975 and 2014 in the NCD-RisC databases, 448 
had measured FPG but only 59 had measured 2hOGTT; 
33% of surveys before 1990 had 2hOGTT and only 11% 
did after 1990. Therefore, a strategy for consistent and 
comparable surveillance is to use FPG in population-
based surveys, be it national or multicountry survey 
programmes such as the WHO STEPS surveys, and 
deﬁ ne diabetes based on FPG. Data such as those in 
ﬁ gure 2 and table 1 can then be used to relate prevalences 
based on FPG to those based on FPG-or-2hOGTT. The 
use of HbA1c in surveillance requires further 
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consideration of how it predicts and helps prevent 
diabetes complications and sequelae. When HbA1c is 
used, FPG should ideally also be measured in a 
subsample of participants to provide information about 
how the two tests relate.
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